Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

October 01, 2020

Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™

September 15, 2020

Metacrine Announces Pricing of Initial Public Offering

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.